MX2021011007A - Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. - Google Patents
Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco.Info
- Publication number
- MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A MX 2021011007 A MX2021011007 A MX 2021011007A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- diabetes
- treating
- preventing complications
- complications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019044670 | 2019-03-12 | ||
| PCT/JP2020/010967 WO2020184691A1 (ja) | 2019-03-12 | 2020-03-12 | 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011007A true MX2021011007A (es) | 2022-03-11 |
Family
ID=72426033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011007A MX2021011007A (es) | 2019-03-12 | 2020-03-12 | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220040294A (ko) * | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
| US20240190896A1 (en) * | 2021-02-10 | 2024-06-13 | Shanghai Senhui Medicine Co., Ltd. | Smtp-7 derivative and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05176782A (ja) * | 1992-01-08 | 1993-07-20 | Taisho Pharmaceut Co Ltd | Ｎｇｆ作用増強因子 |
| JP4313049B2 (ja) * | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| CA2625340A1 (en) | 2005-10-06 | 2007-04-12 | National University Corporation Tokyo University Of Agriculture And Tech Nology | Pharmaceutical composition for treatment or prevention of nephritis and method for producing same |
| EP2604697B1 (en) | 2006-03-27 | 2015-07-01 | Tokyo University of Agriculture and Technology TLO | Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer |
| WO2010110026A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東京農工大学 | メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物 |
| USRE47684E1 (en) * | 2009-07-06 | 2019-11-05 | Tms Co., Ltd. | Cytoprotective agent |
| WO2011125930A1 (ja) * | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
| WO2012115209A1 (ja) * | 2011-02-24 | 2012-08-30 | 国立大学法人東京農工大学 | 可溶性エポキシドハイドロラーゼ阻害剤 |
| JP2019044670A (ja) | 2017-08-31 | 2019-03-22 | スズキ株式会社 | 内燃機関の排出ガス浄化システム |
-
2020
- 2020-03-12 AU AU2020238177A patent/AU2020238177A1/en not_active Abandoned
- 2020-03-12 CA CA3133204A patent/CA3133204A1/en active Pending
- 2020-03-12 KR KR1020217032312A patent/KR20220009371A/ko unknown
- 2020-03-12 PE PE2021001508A patent/PE20220333A1/es unknown
- 2020-03-12 SG SG11202109982Y patent/SG11202109982YA/en unknown
- 2020-03-12 EP EP20771088.0A patent/EP3939659A4/en not_active Withdrawn
- 2020-03-12 WO PCT/JP2020/010967 patent/WO2020184691A1/ja unknown
- 2020-03-12 JP JP2021505150A patent/JPWO2020184691A1/ja not_active Withdrawn
- 2020-03-12 MX MX2021011007A patent/MX2021011007A/es unknown
- 2020-03-12 US US17/438,801 patent/US20220218664A1/en active Pending
- 2020-03-12 EA EA202192483A patent/EA202192483A1/ru unknown
- 2020-03-12 BR BR112021018084A patent/BR112021018084A8/pt unknown
- 2020-03-12 CN CN202080035808.7A patent/CN114126711A/zh active Pending
-
2021
- 2021-09-10 CL CL2021002373A patent/CL2021002373A1/es unknown
- 2021-09-12 IL IL286289A patent/IL286289A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020184691A1 (US07321065-20080122-C00160.png) | 2020-09-17 |
| EA202192483A1 (ru) | 2021-12-24 |
| EP3939659A4 (en) | 2022-12-21 |
| KR20220009371A (ko) | 2022-01-24 |
| CA3133204A1 (en) | 2020-09-17 |
| PE20220333A1 (es) | 2022-03-14 |
| BR112021018084A8 (pt) | 2022-10-04 |
| BR112021018084A2 (US07321065-20080122-C00160.png) | 2021-12-21 |
| IL286289A (en) | 2021-10-31 |
| SG11202109982YA (en) | 2021-10-28 |
| CL2021002373A1 (es) | 2022-06-17 |
| AU2020238177A1 (en) | 2021-11-04 |
| WO2020184691A1 (ja) | 2020-09-17 |
| US20220218664A1 (en) | 2022-07-14 |
| CN114126711A (zh) | 2022-03-01 |
| EP3939659A1 (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500673A1 (en) | Compounds | |
| MY190137A (en) | Noxious organism control agent composition for agricultural and horticultural applications, and method for using said composition | |
| EP4269440A3 (en) | Composition for treating il-6-related diseases | |
| MX2021006695A (es) | Moduladores de trex1. | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| SG11201810704WA (en) | Sulfonamide compound or salt thereof | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| MX2021003686A (es) | Medicamento para el tratamiento de la tos cronica. | |
| PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| MX2021004474A (es) | Compuestos que contienen deuterio. | |
| MX2021011007A (es) | Farmaco y método para tratar o prevenir las complicaciones de la diabetes mediante el uso del mismo farmaco. | |
| MX2024002885A (es) | Inhibidor de la proteasa 3clpro. | |
| MX2024006991A (es) | Composiciones farmaceuticas inyectables y usos de las mismas. | |
| MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
| PH12019502078A1 (en) | Plant disease control agent | |
| MX2022008665A (es) | Nuevo derivado de pirazol. | |
| PH12016501906A1 (en) | Pyrimidine compound | |
| MX2020006055A (es) | Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas. | |
| GEP20247590B (en) | Antibacterial quinolines | |
| AU2017370226A1 (en) | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| CR20220006A (es) | Compuestos para tratar enfermedad respiratoria | |
| WO2018102256A8 (en) | Pyrrolidinone compounds |